Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study
Yu Zhou,1 Mingyu Chen,1 Libin Liu,2 Zhou Chen1 1Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fujian Medical University, Fuzhou, People’s Republic of China; 2Department of Endocrinology, Fujian Medical University Union Hospital, Fuzhou, People’s Republic of ChinaCo...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2022-01-01
|
| Series: | Diabetes, Metabolic Syndrome and Obesity |
| Subjects: | |
| Online Access: | https://www.dovepress.com/difference-in-gastrointestinal-risk-associated-with-use-of-glp-1-recep-peer-reviewed-fulltext-article-DMSO |
| _version_ | 1811173913839796224 |
|---|---|
| author | Zhou Y Chen M Liu L Chen Z |
| author_facet | Zhou Y Chen M Liu L Chen Z |
| author_sort | Zhou Y |
| collection | DOAJ |
| description | Yu Zhou,1 Mingyu Chen,1 Libin Liu,2 Zhou Chen1 1Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fujian Medical University, Fuzhou, People’s Republic of China; 2Department of Endocrinology, Fujian Medical University Union Hospital, Fuzhou, People’s Republic of ChinaCorrespondence: Zhou Chen; Libin Liu Tel +86-591-22862587; +86-591-86218562Email chenzhou@fjmu.edu.cn; libinliu@fjmu.edu.cnBackground: Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are promising weight-loss drugs, but real-world data concerning the liability of GLP-1RAs in gastrointestinal safety are lacking. We examined the differences in gastrointestinal safety between semaglutide and liraglutide.Materials and Methods: We used the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database and retrieved data during the first three years of semaglutide and liraglutide approved by the FDA. Thirteen main gastrointestinal adverse drug reactions (GADRs) were evaluated. Patient demographics, treatment information, and outcome of events were summarized. Disproportionality analyses were conducted by estimating the reporting odds ratios (RORs) and 95% confidence intervals (CIs).Results: In the reported cases of semaglutide (n = 2047) and liraglutide (n = 4175), semaglutide had a higher pooled ROR and later pooled time-to-onset median of GADRs compared with those of liraglutide (5.53, 95% CI 5.23– 5.85 vs 3.95, 95% CI 3.81– 4.10; 7 days, Q1–Q3: 0– 48 vs 4 days, Q1–Q3: 0– 34.5). The thirteen GADRs associated with these two GLP-1RAs showed a significant difference in the profile of reporting risk and time-to-onset.Conclusion: GLP-1RAs produce a spectrum of distinct classes of GADRs. The individual properties of GADRs between semaglutide and liraglutide might enable incretin-based treatment of obesity to be “tailored” to the needs of each patient.Keywords: GLP-1 receptor agonists, gastrointestinal adverse drug reactions, pharmacovigilance database |
| first_indexed | 2024-04-10T17:54:43Z |
| format | Article |
| id | doaj.art-1516b354a90c4fcc8927a85abe4b137c |
| institution | Directory Open Access Journal |
| issn | 1178-7007 |
| language | English |
| last_indexed | 2024-04-10T17:54:43Z |
| publishDate | 2022-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Diabetes, Metabolic Syndrome and Obesity |
| spelling | doaj.art-1516b354a90c4fcc8927a85abe4b137c2023-02-02T18:44:26ZengDove Medical PressDiabetes, Metabolic Syndrome and Obesity1178-70072022-01-01Volume 1515516372258Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance StudyZhou YChen MLiu LChen ZYu Zhou,1 Mingyu Chen,1 Libin Liu,2 Zhou Chen1 1Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fujian Medical University, Fuzhou, People’s Republic of China; 2Department of Endocrinology, Fujian Medical University Union Hospital, Fuzhou, People’s Republic of ChinaCorrespondence: Zhou Chen; Libin Liu Tel +86-591-22862587; +86-591-86218562Email chenzhou@fjmu.edu.cn; libinliu@fjmu.edu.cnBackground: Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are promising weight-loss drugs, but real-world data concerning the liability of GLP-1RAs in gastrointestinal safety are lacking. We examined the differences in gastrointestinal safety between semaglutide and liraglutide.Materials and Methods: We used the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database and retrieved data during the first three years of semaglutide and liraglutide approved by the FDA. Thirteen main gastrointestinal adverse drug reactions (GADRs) were evaluated. Patient demographics, treatment information, and outcome of events were summarized. Disproportionality analyses were conducted by estimating the reporting odds ratios (RORs) and 95% confidence intervals (CIs).Results: In the reported cases of semaglutide (n = 2047) and liraglutide (n = 4175), semaglutide had a higher pooled ROR and later pooled time-to-onset median of GADRs compared with those of liraglutide (5.53, 95% CI 5.23– 5.85 vs 3.95, 95% CI 3.81– 4.10; 7 days, Q1–Q3: 0– 48 vs 4 days, Q1–Q3: 0– 34.5). The thirteen GADRs associated with these two GLP-1RAs showed a significant difference in the profile of reporting risk and time-to-onset.Conclusion: GLP-1RAs produce a spectrum of distinct classes of GADRs. The individual properties of GADRs between semaglutide and liraglutide might enable incretin-based treatment of obesity to be “tailored” to the needs of each patient.Keywords: GLP-1 receptor agonists, gastrointestinal adverse drug reactions, pharmacovigilance databasehttps://www.dovepress.com/difference-in-gastrointestinal-risk-associated-with-use-of-glp-1-recep-peer-reviewed-fulltext-article-DMSOglp-1 receptor agonistsgastrointestinal adverse drug reactionspharmacovigilance database |
| spellingShingle | Zhou Y Chen M Liu L Chen Z Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study Diabetes, Metabolic Syndrome and Obesity glp-1 receptor agonists gastrointestinal adverse drug reactions pharmacovigilance database |
| title | Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study |
| title_full | Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study |
| title_fullStr | Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study |
| title_full_unstemmed | Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study |
| title_short | Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study |
| title_sort | difference in gastrointestinal risk associated with use of glp 1 receptor agonists a real world pharmacovigilance study |
| topic | glp-1 receptor agonists gastrointestinal adverse drug reactions pharmacovigilance database |
| url | https://www.dovepress.com/difference-in-gastrointestinal-risk-associated-with-use-of-glp-1-recep-peer-reviewed-fulltext-article-DMSO |
| work_keys_str_mv | AT zhouy differenceingastrointestinalriskassociatedwithuseofglp1receptoragonistsarealworldpharmacovigilancestudy AT chenm differenceingastrointestinalriskassociatedwithuseofglp1receptoragonistsarealworldpharmacovigilancestudy AT liul differenceingastrointestinalriskassociatedwithuseofglp1receptoragonistsarealworldpharmacovigilancestudy AT chenz differenceingastrointestinalriskassociatedwithuseofglp1receptoragonistsarealworldpharmacovigilancestudy |